$5.85
-0.14-2.34%
At Close: -
$5.80
-0.05-0.79%
After Hours: 4:55 PM EDT
15 minutes delayed
Revance Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Revance Therapeutics using advanced sorting and filters.
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-08 | $-0.36 | $-0.53 | 32.1 % |
Mar 2024 | 2024-05-09 | $-0.54 | $-0.75 | 28.0 % |
Dec 2023 | 2024-02-28 | $-0.62 | $-0.72 | 13.9 % |
Sep 2023 | 2023-11-08 | $-0.55 | $-0.90 | 38.9 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-08 | $65.39M | $66.06M | -1.02 % |
Mar 2024 | 2024-05-09 | $51.94M | $56.63M | -8.29 % |
Dec 2023 | 2024-02-28 | $69.80M | $62.63M | 11.5 % |
Sep 2023 | 2023-11-08 | $56.78M | $60.38M | -5.97 % |
Revance Therapeutics (RVNC) is scheduled to report earnings on November 6, 2024. The last reported earnings were for reported on August 8, 2024 for Q2.
The Actual EPS was $-0.36, which beat the estimate of $-0.53.
The Actual Revenue was $65.4M, which missed the estimate of $66.1M.
Browse earnings estimates, EPS, and revenue on all stocks.